Benchmark Reiterates Speculative Buy on Biolase, Maintains $0.4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Biolase (OTC:BIOL) and maintained a price target of $0.4.
October 02, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Biolase, maintaining a price target of $0.4. This suggests confidence in the company's potential despite its speculative nature.
The reiteration of a Speculative Buy rating and maintenance of a $0.4 price target by Benchmark indicates continued confidence in Biolase's potential. This could positively influence investor sentiment and potentially lead to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100